DAHOS Study: Efficacy of dapagliflozin in treating heart failure with reduced ejection fraction and obstructive sleep apnea syndrome — A 3-month, multicenter, randomized controlled clinical trial

ConclusionsDapagliflozin may be an effective treatment for heart failure complicated with OSA, and could be considered as a potential new treatment for OSA. (Trial registration  www.chictr.org.cn,  ChiCTR2100049834. Registered 10 August 2021).
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research